|

Tyrosine kinase inhibitor Clinical Trials

3 actively recruiting trials across 1 location

Pipeline

Phase 2: 1Phase 3: 1

Top Sponsors

  • University of Colorado, Denver1
  • Tata Memorial Hospital1
  • Institute of Hematology & Blood Diseases Hospital, China1

Indications

  • Cancer3
  • Lung Cancer2
  • Driver Mutation Positive Non-small Cell Lung Cancer1
  • Asymptomatic Brain Metastases1
  • Acute Leukemia of Ambiguous Lineage1

Other2 trials

Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage
Phase 2
Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT
Phase 3

Aurora, Colorado1 trial

Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.

University of Colorado Hospital

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.